Tag Archives: Doron Therapeutics

Doron Therapeutics Positive Phase 2 End Of Phase Meeting 2025

BIOTECH

Doron Therapeutics Announces Positive End-of-Phase 2 and Initial RMAT Meeting With FDA for MOTYS (PTP-001) in the Treatment of Knee Osteoarthritis
May 20, 2025

CHAPEL HILL, NORTH CAROLINA / ACCESS Newswire / May 20, 2025 / Doron Therapeutics, a clinical-stage biotechnology company...

Read more
Doron Therapeutics 11m Series A Osteoporosis Drug Phase 3 Clinical Study

BIOTECH

Doron Therapeutics Raises $11M Series A to Progress Biologic Regenerative Osteoarthritis Drug into Phase 3 Clinical Studies
November 25, 2024

CHAPEL HILL, NC / ACCESSWIRE / November 25, 2024 / Doron Therapeutics, a clinical-stage biotech company...

Read more
This site uses cookies to offer you a better browsing experience. By browsing this website, you agree to our use of cookies.
Accept